By Dr Emmy Dorothee Grace Fleuren

Journal articles

Lau LMS; Khuong-Quang DA; Mayoh C; Wong M; Barahona P; Ajuyah P; Senapati A; Nagabushan S; Sherstyuk A; Altekoester AK; Fuentes-Bolanos NA; Yeung V; Sullivan A; Omer N; Diamond Y; Jessop S; Battaglia L; Zhukova N; Cui L; Lin A; Gifford AJ; Fleuren EDG; Dalla-Pozza L; Moore AS; Khaw SL; Eisenstat DD; Gottardo NG; Wood PJ; Tapp H; Alvaro F; McCowage G; Nicholls W; Hansford JR; Manoharan N; Kotecha RS; Mateos MK; Lock RB; Tyrrell V; Haber M; Trahair TN; Cowley MJ; Ekert PG; Marshall GM; Ziegler DS, 2024, 'Precision-guided treatment in high-risk pediatric cancers', Nature Medicine, pp. 1 - 10, http://dx.doi.org/10.1038/s41591-024-03044-0

Brown LM; Ekert PG; Fleuren EDG, 2023, 'Biological and clinical implications of FGFR aberrations in paediatric and young adult cancers', Oncogene, 42, pp. 1875 - 1888, http://dx.doi.org/10.1038/s41388-023-02705-7

Fleuren EDG; Vlenterie M; van der Graaf WTA, 2023, 'Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma', Frontiers in Oncology, 13, http://dx.doi.org/10.3389/fonc.2023.1013359

Van Erp AEM; Hillebrandt-Roeffen MHS; Van Bree NFHN; Plüm TA; Flucke UE; Desar IME; Fleuren EDG; Van Der Graaf WTA; Versleijen-Jonkers YMH, 2022, 'Targeting the FAK-Src Complex in Desmoplastic Small Round Cell Tumors, Ewing Sarcoma, and Rhabdomyosarcoma', Sarcoma, 2022, http://dx.doi.org/10.1155/2022/3089424

Fleuren EDG; Terry RL; Meyran D; Omer N; Trapani JA; Haber M; Neeson PJ; Ekert PG, 2021, 'Enhancing the potential of immunotherapy in paediatric sarcomas: Breaking the immunosuppressive barrier with receptor tyrosine kinase inhibitors', Biomedicines, 9, pp. 1798, http://dx.doi.org/10.3390/biomedicines9121798

Fordham AM; Ekert PG; Fleuren EDG, 2021, 'Precision medicine and phosphoproteomics for the identification of novel targeted therapeutic avenues in sarcomas', Biochimica et Biophysica Acta - Reviews on Cancer, 1876, http://dx.doi.org/10.1016/j.bbcan.2021.188613

Terry RL; Meyran D; Fleuren EDG; Mayoh C; Zhu J; Omer N; Ziegler DS; Haber M; Darcy PK; Trapani JA; Neeson PJ; Ekert PG, 2021, 'Chimeric antigen receptor t cell therapy and the immunosuppressive tumor microenvironment in pediatric sarcoma', Cancers, 13, pp. 4704, http://dx.doi.org/10.3390/cancers13184704

Wong M; Mayoh C; Lau LMS; Khuong-Quang DA; Pinese M; Kumar A; Barahona P; Wilkie EE; Sullivan P; Bowen-James R; Syed M; Martincorena I; Abascal F; Sherstyuk A; Bolanos NA; Baber J; Priestley P; Dolman MEM; Fleuren EDG; Gauthier ME; Mould EVA; Gayevskiy V; Gifford AJ; Grebert-Wade D; Strong PA; Manouvrier E; Warby M; Thomas DM; Kirk J; Tucker K; O’Brien T; Alvaro F; McCowage GB; Dalla-Pozza L; Gottardo NG; Tapp H; Wood P; Khaw SL; Hansford JR; Moore AS; Norris MD; Trahair TN; Lock RB; Tyrrell V; Haber M; Marshall GM; Ziegler DS; Ekert PG; Cowley MJ; O'Brien T; Wong-Erasmus M, 2020, 'Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer', Nature Medicine, 26, pp. 1742 - 1753, http://dx.doi.org/10.1038/s41591-020-1072-4

van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA, 2020, 'Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo', Journal of Cancer Research and Clinical Oncology, 146, pp. 1659 - 1670, http://dx.doi.org/10.1007/s00432-020-03211-z

Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; Von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; Van Der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ, 2018, 'Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-29043-z

Holme H; Gulati A; Brough R; Fleuren EDG; Bajrami I; Campbell J; Chong IY; Costa-Cabral S; Elliott R; Fenton T; Frankum J; Jones SE; Menon M; Miller R; Pemberton HN; Postel-Vinay S; Rafiq R; Selfe JL; von Kriegsheim A; Munoz AG; Rodriguez J; Shipley J; van der Graaf WTA; Williamson CT; Ryan CJ; Pettitt S; Ashworth A; Strauss SJ; Lord CJ, 2018, 'Erratum to: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness (Scientific Reports, (2018), 8, 1, (10614), 10.1038/s41598-018-29043-z)', Scientific Reports, 8, http://dx.doi.org/10.1038/s41598-018-30922-8

Van Erp AEM; Versleijen-Jonkers YMH; Van Der Graaf WTA; Fleuren EDG, 2018, 'Targeted therapy-based combination treatment in rhabdomyosarcoma', Molecular Cancer Therapeutics, 17, pp. 1365 - 1380, http://dx.doi.org/10.1158/1535-7163.MCT-17-1131

Desar IME; Fleuren EDG; van der Graaf WTA, 2018, 'Systemic Treatment for Adults with Synovial Sarcoma', Current Treatment Options in Oncology, 19, http://dx.doi.org/10.1007/s11864-018-0525-1

Brandsma I; Fleuren EDG; Williamson CT; Lord CJ, 2017, 'Directing the use of DDR kinase inhibitors in cancer treatment', Expert Opinion on Investigational Drugs, 26, pp. 1341 - 1355, http://dx.doi.org/10.1080/13543784.2017.1389895

van Erp AEM; Hillebrandt-Roeffen MHS; van Houdt L; Fleuren EDG; van der Graaf WTA; Versleijen-Jonkers YMH, 2017, 'Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib', Targeted Oncology, 12, pp. 815 - 826, http://dx.doi.org/10.1007/s11523-017-0528-z

Fleuren EDG; Vlenterie M; Van Der Graaf WTA; Hillebrandt-Roeffen MHS; Blackburn J; Ma X; Chan H; Magias MC; Van Erp A; Van Houdt L; Cebeci SAS; Van De Ven A; Flucke UE; Heyer EE; Thomas DM; Lord CJ; Marini KD; Vaghjiani V; Mercer TR; Cain JE; Wu J; Versleijen-Jonkers YMH; Daly RJ, 2017, 'Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes', Cancer Research, 77, pp. 4279 - 4292, http://dx.doi.org/10.1158/0008-5472.CAN-16-2550

Jones SE; Fleuren EDG; Frankum J; Konde A; Williamson CT; Krastev DB; Pemberton HN; Campbell J; Gulati A; Elliott R; Menon M; Selfe JL; Brough R; Pettitt SJ; Niedzwiedz W; Van Der Graaf WTA; Shipley J; Ashworth A; Lord CJ, 2017, 'ATR Is a therapeutic target in synovial sarcoma', Cancer Research, 77, pp. 7014 - 7026, http://dx.doi.org/10.1158/0008-5472.CAN-17-2056

Vlenterie M; Hillebrandt-Roeffen MHS; Schaars EWM; Flucke UE; Fleuren EDG; Navis AC; Leenders WPJ; Versleijen-Jonkers YMH; van der Graaf WTA, 2016, 'Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients', Annals of Surgical Oncology, 23, pp. 2745 - 2752, http://dx.doi.org/10.1245/s10434-016-5341-x

Kager L; Whelan J; Dirksen U; Hassan B; Anninga J; Bennister L; Bovee JVMG; Brennan B; Broto JM; Brugieres L; Cleton-Jansen A-M; Copland C; Dutour A; Fagioli F; Ferrari S; Fiocco M; Fleuren E; Gaspar N; Gelderblom H; Gerrand C; Gerss J; Gonzato O; van der Graaf W; Hecker-Nolting S; Herrero-Martin D; Klco-Brosius S; Kovar H; Ladenstein R; Lancia C; LeDeley M-C; McCabe MG; Metzler M; Myklebost O; Nathrath M; Picci P; Potratz J; Redini F; Richter GHS; Reinke D; Rutkowski P; Scotlandi K; Strauss S; Thomas D; Tirado OM; Tirode F; Vassal G; Bielack SS, 2016, 'The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report', CLINICAL SARCOMA RESEARCH, 6, http://dx.doi.org/10.1186/s13569-016-0043-5

Fleuren EDG; Zhang L; Wu J; Daly RJ, 2016, 'The kinome 'at large' in cancer', Nature Reviews Cancer, 16, pp. 83 - 98, http://dx.doi.org/10.1038/nrc.2015.18

Fleuren EDG; Versleijen-Jonkers YMH; Roeffen MHS; Franssen GM; Flucke UE; Houghton PJ; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2014, 'Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models', International Journal of Cancer, 135, pp. 2770 - 2782, http://dx.doi.org/10.1002/ijc.28933

Fleuren EDG; Versleijen-Jonkers YMH; Heskamp S; van Herpen CML; Oyen WJG; van der Graaf WTA; Boerman OC, 2014, 'Theranostic applications of antibodies in oncology', Molecular Oncology, 8, pp. 799 - 812, http://dx.doi.org/10.1016/j.molonc.2014.03.010

Fleuren EDG; Versleijen-Jonkers YMH; Boerman OC; van der Graaf WTA, 2014, 'Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives', Biochimica et Biophysica Acta - Reviews on Cancer, 1845, pp. 266 - 276, http://dx.doi.org/10.1016/j.bbcan.2014.02.005

Fleuren EDG; Hillebrandt-Roeffen MHS; Flucke UE; te Loo DMWM; Boerman OC; van der Graaf WTA; Versleijen-Jonkers YMH, 2014, 'The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma', Oncotarget, 5, pp. 12753 - 12768, http://dx.doi.org/10.18632/oncotarget.2648

Fleuren EDG; van der Graaf WTA; Roeffen MHS; Flucke UE; Schreuder B; Boerman O; Versleijen-Jonkers YMH, 2014, 'The Role of Axl in Ewing Sarcoma', Annals of Oncology, 25, pp. iv508 - iv508, http://dx.doi.org/10.1093/annonc/mdu354.45

Fleuren EDG; Versleijen-Jonkers YMH; Heskamp S; Roeffen MHS; Bouwman WH; Molkenboer-Kuenen JDM; Van Laarhoven HWM; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2013, 'The strength of small: Improved targeting of Insulin-like Growth Factor-1 Receptor (IGF-1R) with F(ab′)2-R1507 fragments in Ewing sarcomas', European Journal of Cancer, 49, pp. 2851 - 2858, http://dx.doi.org/10.1016/j.ejca.2013.04.009

Fleuren EDG; Roeffen MHS; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; Van Der Graaf WTA; Versleijen-Jonkers YMH, 2013, 'Expression and clinical relevance of MET and ALK in Ewing sarcomas', International Journal of Cancer, 133, pp. 427 - 436, http://dx.doi.org/10.1002/ijc.28047

Fleuren EDG; Versleijen-Jonkers YMH; Van De Luijtgaarden ACM; Molkenboer-Kuenen JDM; Heskamp S; Roeffen MHS; Van Laarhoven HWM; Houghton PJ; Oyen WJG; Boerman OC; Van Der Graaf WTA, 2011, 'Predicting IGF-1R therapy response in bone sarcomas: Immuno-SPECT imaging with radiolabeled R1507', Clinical Cancer Research, 17, pp. 7693 - 7703, http://dx.doi.org/10.1158/1078-0432.CCR-11-1488

Fleuren E; O'Toole S; Millar E; Mcneil CM; Lopez-Knowles E; Boulghourjian A; Croucher DR; Schramek D; Brummer T; Penninger JM; Sutherland RL; Daly RJ, 2010, 'Overexpression of the oncogenic signal transducer Gab2 occurs early in breast cancer development', International Journal of Cancer, 127, pp. 1486 - 1492

Brummer T; Larance M; Abreu MTH; Lyons RJ; Timpson P; Emmerich CH; Fleuren EDG; Lehrbach GM; Schramek D; Guilhaus M; James DE; Daly RJ, 2009, 'The docking protein and proto-oncogene product Gab2 is regulated via a novel negative feedback mechanism mediated by 14-3-3 binding.', Cell communication and signaling : CCS, 7, pp. A12 - A12, http://dx.doi.org/10.1186/1478-811X-7-S1-A12

Brummer T; Larance MC; Abreu M; Lyons RJ; Timpson P; Emmerich C; Fleuren E; Lehrbach GM; Schramek D; Guilhaus M; James DE; Daly RJ, 2008, 'Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein', European Molecular Biology Organization, 27, pp. 2305 - 2316

Back to profile page